Li Ka Shing Knowledge Institute, Toronto, ON
Interns (via teleconference)
Regrets: Bradley Mitchelmore (PHAC), Andrew Beck (ERSC)
Dr. Thombs welcomed the group back to Toronto and thanked them for their attendance. Dr. Thombs asked everyone to introduce themselves. He then reviewed logistical items and reminded attendees of the breakout sessions after the meeting.
Dr. Thombs requested that each speaker should start with a short introduction on the purpose of their presentation. This was to ensure that each presenter acquired the information they needed from the Task Force.
Dr. Moore introduced the members of the Chlamydia & Gonorrhea Working Group. The purpose of this presentation was to review the evidence summary for the Chlamydia & Gonorrhea guideline and the draft recommendation for Task Force approval.
Dr. Einarson will be transitioning off of the Knowledge Translation (KT) team following the meeting. Dr. Einarson introduced other members of the team and presented an overview of recent KT activities. The purpose of the presentation was to provide: an overview of KT work specific to guidelines and KT tools, a re-cap of dissemination activities, updates from the KT working group and information on outreach activities and patient engagement.
Ms. Barnhardt introduced the Communications Team and provided an update on recent Task Force communication activities, initiatives and materials.
Dr. Moore summarized the ECRI (Emergency Care Research Institute) Guideline Trust Assessment of the CTFPHC Guidelines, and the Task Force’s response to comments from the ECRI Institute.
Dr. Groulx presented a brief verbal update on the Esophageal Adenocarcinoma (EAC) guideline. He provided an overview of peer reviewer comments on the guideline recommendation and the Working Group’s responses to those comments.
Dr. Persaud introduced the Potentially Inappropriate Prescribing (PIP) Working Group members. The purpose of this presentation was to acquire Task Force feedback and approval for Key Questions 1 & 2 and the PICO table for Key Question 1.
Dr. Traversy provided an update on the Methods Working Group activities, particular their work around Conflicts of Interest (COI). The Methods Working Group has recently discussed and approved some elements of the updated COI policy: definitions around COIs and the types of interest, and the proposed options to manage COIs once identified amongst Task Force members. The Working Group was seeking Task Force approval on these two items, with the intent of applying this new approach to discussions moving forward.
Dr. Lang introduced and thanked the Depression (Pregnancy/ Postpartum) Working Group and led a discussion with the aim of seeking feedback from the Task Force on the wording of the guideline recommendation.
Dr. Riva summarized Key Questions that had previously been discussed with the Task Force. As result of the last meeting the Working Group was looking for feedback on feasibility, rigor, budget and timeline. The purpose of this presentation was to provide an update on KT (Knowledge Translation) activities and review the proposed methods to address large volume of information collected for KQ 1 (on effectiveness). The Working Group was seeking Task Force approval for the revised Key Questions and PICOs.
Dr. Wilson provided an update on the Hypertension guideline and explained that the main purpose of the presentation was to seek Task Force approval for the Key Questions and PICOs.
Dr. LeBlanc led this presentation to provide a status update on the systematic review draft protocol and provided an overview of stakeholder and peer reviewer comments on this document. The Working Group was looking for Task Force approval for their responses to these comments and for initiating the search (i.e. systematic review).
Dr. Lang provided a verbal update on the current status of the Depression in Adults guideline. Dr. Lang summarized the rationale behind the Working Group’s decision on the strength and direction of the guideline recommendation.
Dr. Reynolds introduced the Working Group and thanked them for their work. Dr. Reynolds provided background information on Cervical Cancer and looked for Task Force approval and feedback on Key Questions and PICOs (including outcomes).
Ms. Pillay presented the initial analysis results and the GRADE assessments for Key Question 1 of the Fragility Fracture guideline
Dr. Thombs thanked all the Working Groups, presenters and organizers of the meeting. Dr. Thombs thanked and applauded Dr. Groulx and Dr. Einarson for their insights, hard work and valuable contributions towards the Task Force. The Task Force joined Dr. Thombs in thanking them and bidding them farewell. Dr. Groulx will continue to be involved in the Task Force as a Working Group member for the Esophageal Cancer, Hypertension and Tobacco guidelines, as well as assisting KT with guideline translation efforts (English to French).
The next Task Force in-person meeting will be taking place in Toronto, ON on February 10-11th, 2020.